ÂÜÀòÂÒÂ×

Yongjian Wu, PhD, currently serves as Chief Development Officer at MBrace Therapeutics, a position held since April 2022. Previously, Wu was VP of CMC at Ansun Biopharma, Inc. from August 2020 to April 2022, and Chief Operating Officer at MabPlex USA from October 2019 to August 2020. From September 2011 to October 2019, Wu held the role of Chief Scientific Officer and Vice President of Research and Development at Tanvex Biopharma USA, Inc., focusing on strategic planning, process development for biosimilars, and regulatory interactions. Earlier experience includes roles in analytical sciences at Genentech and research at BioMarin and Bayer. Yongjian Wu earned a PhD in Immunology from the University of Toronto and a BSc in Biochemistry from the same institution, with foundational studies at Fudan University.